목적: 변성근시에 동반된 맥락막혈관신생에서 유리체강내 bevacizumab 주입술의 단기결과를 알아보았다.
대상과 방법: 15명, 15안을 대상으로 bevacizumab 주사를 1회 또는 연속된 2회를 시행하였다. 치료 전, 후 한 달 간격으로 교정시력과
안저검사를 시행했고, 형광안저혈관조영은 치료 전과 치료 후 1개월, 3개월째 시행하였다. 1차 주사 후 1개월째 형광누출이 지속된
경우 2차 주사를 시행했다.
결과: 평균 경과관찰은 9.7개월이었고, logMAR 교정시력은 치료 전 0.81±0.44, 3개월째 0.64±0.41 (p=0.005), 최종 경과관찰 시
0.60±0.41 (p=0.001)이었다. 5안은 1회, 10안은 2회의 연속된 주사를 시행하였다. 1차 주사 후 3개월째 14안(93.3%)에서 형광누출이
소실되었고, 1안(6.7%)은 누출이 감소하였다. 치료 후 3개월과 최종 경과관찰에서 각각 1.7줄과 2.1줄의 시력호전을 보였고, 경과관찰
중 시력이 감소한 경우는 없었다.
결론: 1회 또는 연속된 2회의 유리체강내 bevacizumab 주사는 혈관신생과 연관된 변성근시에서 단기적인 시력의 안정화와 맥락막혈관신생의
퇴행에 효과적이다.Purpose: To investigate the short-term effect of intravitreal bevacizumab injection for choroidal neovascularization associated with
degenerative myopia.
Methods: In 15 eyes of 15 patients, one or two consecutive intravitreal bevacizumab injections were given. The best-corrected
visual acuity (BCVA) and fundus examination were evaluated at baseline and monthly thereafter. Fluorescence angiography (FA)
was performed at baseline, 1 month and 3 months after treatment. When the angiographic leakage persisted 1 month after the
first injection, a second injection was administered.
Results: The mean follow-up period was 9.7 months. The mean logarithm of the minimum angle of resolution (LogMAR) BCVA
was 0.81?.44 at baseline, 0.64?.41 at 3 months (p=0.005), and 0.60?.41 (p=0.001) at the final examination. Five eyes
received a single injection, while the other ten eyes had two consecutive injections. Three months after the first injection, 14 eyes
(93.3%) had no angiographic leakage, and 1 eye (6.7%) showed a decrease in leakage. The mean lines of visual improvement
at 3 months and at the final examination were 1.7 and 2.1 lines, respectively. No case of vision loss was observed throughout
the follow-up period.
Conclusions: One or two consecutive intravitreal bevacizumab injections had favorable short-term effects on visual acuity
stabilization and the regression of choroidal neovascularization associated with neovascular degenerative myopia.